PROs Support Practice-Changing RUBY Trial in Endometrial Cancer
Adding dostarlimab upfront does not add significant toxicity for patients, says Pamela Soliman
Source: medpagetoday.com
Stay updated with breaking news from Greg Laub. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adding dostarlimab upfront does not add significant toxicity for patients, says Pamela Soliman
Kathryn Beckermann, MD, shares insights on the evolving treatment landscape in metastatic RCC
Ian Flinn, MD, PhD, leads a discussion on the future successors to the current standard of care
Simone Thavaseelan points out that it takes hard work to make leadership in urology more diverse
Our expert roundtable dives into the JAK inhibitor's new indication